Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Evaluating factors predicting survival in patients of NSCLC with poor performanc...
Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
Evaluating factors predicting survival in patients of NSCLC with poor performance status in resource-constrained settings ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )
5 Aug 2021
OncoAlert and ecancer weekly round up for July 19 - July 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for July 19 - July 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Jul 2021
Part 3: How to test
PARP inhibition in the treatment of prostate cancer
Part 3: How to test ( PARP inhibition in the treatment of prostate cancer )
23 Jul 2021
OncoAlert and ecancer weekly round up for July 12- July 18, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for July 12- July 18, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Jul 2021
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invas...
Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invasive bladder cancer ( Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy )
19 Jul 2021
Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600...
Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain
Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer ( Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain )
13 Jul 2021
ASCO 2021: Precision and molecular reporting for prostate cancer
Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA
ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )
29 Jun 2021
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC
Dr Christina Baik - University of Washington School of Medicine, Seattle, USA
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )
11 Jun 2021
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...
Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )
11 Jun 2021